Genoss DES Prospective Multicenter Registry

CompletedOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

November 18, 2016

Primary Completion Date

November 29, 2021

Study Completion Date

December 31, 2022

Conditions
Coronary Artery DiseaseMyocardial IschemiaMyocardial Infarction
Interventions
DEVICE

Genoss DES

The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Trial Locations (17)

220060

Wonju Severance Christian Hospital, Wŏnju

Unknown

Chungbuk National University Hospital, Cheongju-si

Dankook University Hospital, Cheonan

Chuncheon Sacred Heart Hospital, Chuncheon

Kangwon National University Hospital, Chuncheon

Gangneung Asan Hospital, Gangneung

Inje University Ilsan Paik Hospital, Goyang-si

Myongji Hospital, Hanyang University College of Medicine, Goyang-si

National Health Insurance Service Ilsan Hospital, Goyang-si

CHA Bundang Medical Center, Seongnam-si

Kosin University Gospel Hospital, Busan

Gachon University Gil Medical Center, Incheon

Ewha Womans University Mokdong Hospital, Seoul

Gangnam Severance Hospital, Seoul

Kangnam Sacred Heart Hospital, Seoul

Korea University Anam Hospital, Seoul

Severance Cardiovascular Hospital, Seoul

All Listed Sponsors
collaborator

Genoss Co., Ltd.

INDUSTRY

lead

Young Jin Youn, MD, PhD

OTHER

NCT03045913 - Genoss DES Prospective Multicenter Registry | Biotech Hunter | Biotech Hunter